A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer

Trial Profile

A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Pazopanib (Primary) ; Paclitaxel
  • Indications Thyroid cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 03 Sep 2013 Planned end date changed from 1 Oct 2018 to 1 Dec 2019 as reported by ClinicalTrials.gov.
    • 03 Sep 2013 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top